Effect of Subcutaneous Tocilizumab on Mortality in Patients With COVID-19: A Meta-analysis of Retrospective Cohort Studies.

Am J Ther

Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical, Foundation, New Taipei City, Republic of China.

Published: July 2021

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415518PMC
http://dx.doi.org/10.1097/MJT.0000000000001434DOI Listing

Publication Analysis

Top Keywords

subcutaneous tocilizumab
4
tocilizumab mortality
4
mortality patients
4
patients covid-19
4
covid-19 meta-analysis
4
meta-analysis retrospective
4
retrospective cohort
4
cohort studies
4
subcutaneous
1
mortality
1

Similar Publications

Objectives: The feasibility of corticosteroid withdrawal (CW) for Takayasu arteritis (TAK) remains uncertain. Two autoantibodies (Abs) are identified against endothelial protein C receptor (EPCR) and scavenger receptor class B type 1 (SR-BI) in TAK, determining its three subgroups. This study aimed to evaluate CW using tocilizumab (TCZ) and its association with the Ab profile.

View Article and Find Full Text PDF
Article Synopsis
  • Morphea, or localized scleroderma, is an autoimmune disease marked by excessive collagen buildup in the skin, with unclear causes that may include genetic, environmental, and epigenetic factors.
  • Advances in medicine suggest genetic and epigenetic influences may significantly impact the disease's risk and progression, highlighting the role of factors like microRNAs and DNA methylation.
  • New treatment options, including biological therapies and JAK inhibitors, show promise based on case studies, underscoring the need for further exploration of morphea's pathogenesis and treatment strategies.
View Article and Find Full Text PDF

Introduction: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, its management and morbidity impose a great burden to healthcare systems. Development and rollout of biological disease modifying anti-rheumatic drugs has contributed to improvements for patients, however, high costs have prevented them to be widely used. This is being addressed with biosimilars, with equal benefit-risk profile and reduced costs.

View Article and Find Full Text PDF

Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis that can lead to the formation of refractory lower limb ulcers requiring amputation. The standard treatment for severe PAN involves combination therapy with steroids and cyclophosphamide; however, some cases prove to be challenging. Recently, case reports have described the use of biological agents for PAN treatment.

View Article and Find Full Text PDF

Tocilizumab for Advanced Non-Small-Cell Lung Cancer With Concomitant Cachexia: An Observational Study.

J Cachexia Sarcopenia Muscle

December 2024

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: Cancer cachexia significantly contributes to morbidity and mortality in patients with non-small-cell lung cancer (NSCLC). Inflammatory pathways mediated by interleukin-6 (IL-6) play a crucial role in the development of cancer cachexia. This study aimed to investigate the use of tocilizumab in the management of NSCLC with coexisting IL-6-elevated cachexia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!